Fabry disease. A case report

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 14, Issue 1, 2005, Pages 15-19

  Kotnik, Jožica ^a   Kotnik, F ^b   Desnick, R J ^c  

^a General Hospital Slovenj Gradec   (Slovenia)

^b ZPIZ OE Ravne na Koroškem ^*  (Slovenia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

galactosidase A activity; Angiokeratoma corporis diffusum; Enzyme replacement therapy; Fabry disease; X linked recessive inheritance

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; ENZYME REPLACEMENT; FABRY DISEASE; HEART DISEASE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LYSOSOME STORAGE DISEASE; MALE; PROTEINURIA; PURPURA; RECESSIVE INHERITANCE; SLOVENIA; X CHROMOSOME LINKED DISORDER;

ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; FABRY DISEASE; FATAL OUTCOME; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTEINURIA; TIME FACTORS;

EID: 16344381313     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Anderson W. A case of angiokeratoma. Br J Dermatol 1898; 10: 113.
2. Fabry J. Ein Beitrag Zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Habrae). Arch Dermatol Syph 1898; 43: 187.
3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-7.
4. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease In: Scriver CR, Beaudet AL, Sly WS et al, (eds): The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, 2001, p 3733-74.
5. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H. Angiokeratoma corporis diffusum - Fabry's disease. Helv Med Acta 1967; 34: 67-83.
6. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60.
7. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449-55.
8. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395-9.
9. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-93.
10. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez ALD, Eng CE, Tanaka H, Tei C, Desnick RJ. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003; 64: 801-7.
11. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes. α-Galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973; 81: 157-71.
12. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21: 577-81.
13. Ashton-Prolla P, Ashley GA, Giuglianai R, Pires RF, Desnick RJ, Eng CM. Fabry disease: Comparison of enzyzmatic, linkage and mutation analysis in a family with a novel mutation (30 del G). Am J Med Genet 1999; 84: 420-4.
14. Verovnik F, Benko D, Vujkovac B, Linthorst GE. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet 2004; 12: 678-81.
15. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-54.
16. Eng CM, Banikazemi M, Gordon R, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dickman S, Stacy CB, Fallon JT, Brodie S, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68: 711-22.
17. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Eng J Med 2001; 345: 9-16.
18. Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9.
19. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-46.
20. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74.
21. Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004; 122: 900-8.
22. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18: 33-5.
23. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 2003; 348: 1186-7.
24. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299-301.
25. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy. Neurology 2004; 62: 1066-72.
26. Guffon N, Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy: a case series. J Inherit Metab Dis 2004; 27: 221-7.